|
Organogenesis has the skinny on replacement tissue. Flagship product Apligraf is a human skin substitute approved to treat diabetic foot ulcers and venous leg ulcers caused by poor circulation. Rejection-resistant Apligraf is bio-engineered using living skin cells and has been used to treat chronic open wounds in some 200,000 patients; the company is developing a next-generation version of the material (using its VCT technology) using all human components. In addition to Apligraf, Organogenesis offers a line of biomaterials used in a range of surgical procedures to seal or reconstruct soft tissue, and it also develops regenerative technologies in the area of cosmetic skin rejuvenation.
|
| | | Contact Information | |
Address: |
150 Dan Rd.
Canton, MA 02021
| | Phone: | 781-575-0775 | | Fax: | 781-575-0440 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2007): | 13.80 M | | Employees (2007): | 182 |
|
|
Key People
| | • |
President and CEO:
Geoff MacKay
| | • |
EVP, COO, and CFO:
Gary S. Gillheeney Sr.
| | • |
VP Sales, Bio-active Wound Healing:
Santino Costanzo
|
|
|
